Leon Cooperman discloses 6.6% DiaMedica (DMAC) holding

Rhea-AI Filing Summary

DiaMedica Therapeutics investor Leon G. Cooperman reports beneficial ownership of 3,450,000 voting common shares, representing 6.6% of the company’s outstanding shares based on 52,077,439 shares outstanding as of November 10, 2025. The stake consists of 2,450,000 shares held directly by Mr. Cooperman and 1,000,000 shares held by The Leon and Toby Cooperman Foundation, a charitable trust where he is a trustee. He reports sole voting and dispositive power over all 3,450,000 shares and certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of DiaMedica.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:01 PM Learn about SEC filing dates

FAQ

How many DiaMedica Therapeutics (DMAC) shares does Leon Cooperman report owning?

Leon G. Cooperman reports beneficial ownership of 3,450,000 DiaMedica Therapeutics voting common shares. This total combines shares held directly in his name and shares held through The Leon and Toby Cooperman Foundation, where he serves as a trustee.

What percentage of DiaMedica Therapeutics (DMAC) does Leon Cooperman’s stake represent?

Leon G. Cooperman’s reported holdings represent 6.6% of DiaMedica Therapeutics’ voting common shares. This percentage is calculated using 52,077,439 shares outstanding as of November 10, 2025, as disclosed in the company’s Form 10-Q.

How are Leon Cooperman’s DiaMedica (DMAC) shares split between him and his foundation?

Leon G. Cooperman directly holds 2,450,000 DiaMedica voting common shares, while 1,000,000 shares are held by The Leon and Toby Cooperman Foundation, a charitable trust. Together, these positions make up his total reported beneficial ownership.

Does Leon Cooperman have voting control over his DiaMedica Therapeutics (DMAC) shares?

Yes. The filing states that Leon G. Cooperman has sole voting power and sole dispositive power over 3,450,000 DiaMedica shares. He reports no shared voting power and no shared dispositive power over any of the company’s voting common shares.

Is Leon Cooperman’s DiaMedica (DMAC) position intended to influence control of the company?

The filing certifies that the DiaMedica shares were not acquired and are not held for the purpose of changing or influencing control of the company. It also states they are not held in connection with any transaction having that control-related purpose or effect.

What type of SEC filing did Leon Cooperman submit for his DiaMedica (DMAC) holdings?

Leon G. Cooperman submitted an amended Schedule 13G (Amendment No. 2) for DiaMedica Therapeutics. A Schedule 13G is a beneficial ownership report typically used by investors who are not seeking to influence or change control of the issuer.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

DiaMedica Therapeutics Inc.

(Name of Issuer)

Voting Common Shares, no par value

(Title of Class of Securities)

25253X207

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 25253X207

1

Names of Reporting Persons

Cooperman Leon G.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,450,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,450,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,450,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.6 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: DiaMedica Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota, 55305
Item 2.
(a)	Name of person filing: This statement is filed on behalf of Leon G. Cooperman ("Mr. Cooperman"). Mr. Cooperman is engaged in, among other activities, investing for his own account. Mr. Cooperman is married to an individual named Toby Cooperman. Mr. Cooperman is one of the trustees of The Leon and Toby Cooperman Foundation (the "Foundation"), a charitable trust dated December 16, 1981.
(b)	Address or principal business office or, if none, residence: Mr. Cooperman's principal business office address is St. Andrews Country Club, 7118 Melrose Castle Lane, Boca Raton, FL 33496.
(c)	Citizenship: Mr. Cooperman is a United States citizen.
(d)	Title of class of securities: Voting Common Shares, no par value
(e)	CUSIP No.: 25253X207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by this item with respect to the Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. Mr. Cooperman may be deemed the beneficial owner of 3,450,000 Common Shares, which is comprised of: (i) 2,450,000 Common Shares held directly by Mr. Cooperman and (ii) 1,000,000 Common Shares held directly by the Foundation, which collectively constitute approximately 6.6% of the total number of Common Shares outstanding, calculated based on 52,077,439 Common Shares outstanding as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025.
(b)	Percent of class: 6.6%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3,450,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3,450,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Cooperman Leon G.

Signature:	/s/ Edward Levy
Name/Title:	Edward Levy, Attorney-in-Fact
Date:	02/17/2026

Comments accompanying signature: Duly authorized under POA effective as of August 10, 2016 and filed on August 12, 2016.